Large‑scale analyses presented at Kidney Week and published in JAMA show sodium‑glucose cotransporter‑2 (SGLT2) inhibitors confer renal and cardiovascular benefits across a wide range of estimated glomerular filtration rates and albuminuria levels. Researchers reported consistent slowing of kidney function decline and reduced hospitalizations in patients with and without type 2 diabetes. One study quantified benefit across strata of baseline GFR and albuminuria, supporting routine SGLT2 use irrespective of diabetic status in many CKD patients. Another JAMA analysis emphasized effect sizes remain clinically meaningful even at lower GFRs, challenging prior thresholds used to limit prescribing. The data could broaden guideline recommendations and payer coverage, prompting clinicians to reconsider initiation strategies across nephrology and cardiology care pathways.